A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing Tocotrienol-Rich Fraction in healthy human subjects

Puvaneswari Meganathan1,4,5, Rafid Salim Jabir1, Ho Gwo Fuang2, Nirmala Bhoo-Pathy3, Roma Basu Choudhury6, Nur Aishah Taib1, Kalanithi Nesaretnam5 & Zamri Chik4

Gamma and delta tocotrienols are isomers of Vitamin E with established potency in pre-clinical anti-cancer research. This single-dose, randomized, crossover study aimed to compare the safety and bioavailability of a new formulation of Gamma Delta Tocotrienol (GDT) in comparison with the existing Tocotrienol-rich Fraction (TRF) in terms of gamma and delta isomers in healthy volunteers. Subjects were given either two 300 mg GDT (450 mg γ-T3 & 150 mg δ-T3) capsules or four 200 mg TRF (451.2 mg γ-T3 & 102.72 mg δ-T3) capsules and blood samples were taken at several time points over 24 hours. Plasma tocotrienol concentrations were determined using HPLC method. The 90% CI for gamma and delta tocotrienols for the ratio of log-transformation of GDT/TRF for Cmax and AUC0–∞ (values were anti-logged and expressed as a percentage) were beyond the bioequivalence limits (106.21–195.46, 154.11–195.93 and 52.35–99.66, 74.82–89.44 respectively). The Wilcoxon Signed Rank Test for Tmax did not show any significant difference between GDT and TRF for both isomers (p > 0.05). No adverse events were reported during the entire period of study. GDT was found not bioequivalent to TRF, in terms of AUC and Cmax. Gamma tocotrienol in GDT showed superior bioavailability whilst delta tocotrienol showed less bioavailability compared to TRF.

Vitamin E is found in abundance in vegetable oils with tocopherols as the main constituent. In the past, tocopherols have been vastly studied where else there is still paucity in clinical data where tocotrienols are concerned. Palm oil contains about 70% tocotrienols of the vitamin E content; making it one of the richest source of natural tocotrienols. Both tocopherols and tocotrienols have similar structures with the presence of a chromanol ring and a side chain positioned at C-2. Depending on the position and degree of methylation on the chromanol head, tocopherols and tocotrienols can be further differentiated into 4 isomers of α, β, γ and δ respectively. However, tocotrienols possess unsaturated isoprenoid side chain with 3 double bonds at carbon 3, 7 and 11 unlike tocopherols with saturated phytyl chain. This unsaturated side chain of tocotrienols facilitates its efficient penetration into tissues with major composition of fatty layers such as adipose, liver and brain1–3. Research have proven that tocotrienols demonstrate

1Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. 2Oncology Clinical Unit, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. 3Department of Social and Preventive Medicine (SPM), Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. 4Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. 5Malaysian Palm Oil Board (MPOB), No. 6 Persiaran Institusi, Bandar Baru Bangi, 43000 Kajang, Selangor, Malaysia. 6Clinical Investigation Centre, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. Correspondence and requests for materials should be addressed to N.A.T. (email: naisha@um.edu.my)
various biological and physiological properties such as cardioprotective\(^6\), neuroprotective\(^5\), anti-cancer activity\(^8\) and cholesterol-lowering effects\(^7\), therefore distinguishing them from tocopherols.

Bioavailability is defined as the rate and extent of the absorption and availability of the active constituent or its moiety at the target site\(^8\). Alpha-tocopherol is the most abundant form of Vitamin E detected in circulating plasma. Meanwhile, the bioavailability of tocotrienols in plasma has been reported at a much lower concentration than alpha-tocopherol\(^11,12\). The absolute bioavailability of alpha tocotrienol was reported as 28\% followed by gamma and delta tocotrienols at only about 9\%\(^11\). As a result, self-emulsifying systems were established to achieve higher absorption for tocotrienols\(^13\). Tocotrienol-rich Fraction (TRF) [Tocovid Suprabio\(^TM\)], is an over-the-counter vitamin E supplement, containing alpha, gamma and delta tocotrienols in addition to \(\alpha\)-tocopherol, phytosterol, phytocarotenoid complex and plant squalene.

Several anti-cancer studies indicated that gamma and delta tocotrienols exhibited more potent anti-cancer activity than other isomers of tocotrienols and alpha-tocopherol\(^3\). In pre-clinical studies, the IC\(_{50}\) concentration of gamma tocotrienol required to induce apoptosis in both MDA-MB-231 and MCF-7 human breast cancer cell lines was remarkably lower than delta tocotrienol\(^14\). Similar observation was also demonstrated in a study by Guthrie et al.\(^15\) (1998) using MCF-7 cell line, wherein the IC\(_{50}\) concentration of gamma tocotrienol was only 30\(\mu\)g/mL as compared to 90\(\mu\)g/mL of delta tocotrienol indicating increased anti-cancer activity.

Hence, a new formulation of Gamma Delta Tocotrienol (GDT) which contains only gamma and delta isomers (75:25) had been developed in order to improve the effectiveness and enhance the delivery of the gamma and delta isomers as compared to the currently available TRF formulation. Therefore, in this study, we aimed to evaluate the pharmacokinetics and bioavailability of a new formulation of Naturale\(^3\) Gamma Delta Tocotrienol (GDT) with the available Tocotrienol-rich fraction (TRF) in healthy volunteers.

**Subjects and Methods**

**Study design and medications.** This was an open label, randomized, 2-way cross-over study with 2 treatments and 2 periods with one week wash-out period. The study protocol and informed consent forms were reviewed and approved by the medical ethics committee of University Malaya Medical Centre (UMMC) (protocol no:944.62). This study was registered at clinicaltrial.gov with the Identifier NCT01571921 on 26 March 2012. Volunteers were provided with both verbal and written information on the nature of study including the aim of the study, methods to be employed and possible risks related to the drugs. Written consent was obtained prior to the initiation of screening and trial procedures.

The trial protocol was in compliance with Declaration of Helsinki\(^16\), Malaysian Guidelines for Good Clinical Practice\(^17\) and Malaysian Guidelines for the Conduct of Bioavailability and Bioequivalence Studies\(^18\). The volunteers were randomized to receive one of the study formulations. The test formulation, Naturale\(^3\) Gamma delta tocotrienol (GDT) (consist of 2 capsules of 300 mg each containing 450 mg \(\gamma\)-T3 and 150 mg \(\delta\)-T3) was provided by Davos Life Science Pte Ltd, Singapore. The reference drug is the commercially available Tocovid Suprabio\(^TM\) which comprises of 4 capsules of 200 mg containing 451.2 mg \(\gamma\)-T3 and 102.72 mg \(\delta\)-T3 obtained over the shelf.

**Subjects.** Healthy volunteers were recruited through advertisement and medical screening were conducted to exclude any chronic illness or abnormalities, consumption of tobacco, alcohol, drugs and current or past use of any active substance. After a physical examination (to exclude any abnormality of the cardiovascular, respiratory, abdominal and central nervous system), blood pressure and pulse rate were measured and general examination (to rule out anemia, cyanosis, clubbing, jaundice and lymphadenopathy) of the subject was conducted to exclude any illness or abnormality. Resting blood pressure was recorded using a sphygmomanometer while the subject was in a sitting position. Blood sample was collected for full blood count, urea, electrolytes, liver and renal function tests, serology as well as random glucose test. All female volunteers were subjected to urinary pregnancy tests.

The recruitment was based on reviews of pathology reports, medical history and in accordance to inclusion and exclusion criteria. At the end of study, blood sample was drawn again for assessment of all biochemical parameters for safety and tolerability. The subjects were then randomized into reference or test group. Blocked randomization method was used to generate the randomization list. Three blocks with block size of four was used. The drug containers were sequentially numbered and concealed until interventions were assigned.

**Inclusion and exclusion criteria.** The healthy volunteers were recruited based on their age ranging from 21–55 years, in good health based on physical examination and pathological results. They are also literate, provided consent to the study protocols and do not have any reported allergies to vitamin E or palm oil.

The exclusion criteria comprises of pregnant or lactating mothers, chronic illness such as cardiovascular disease or hypertension, present or past history of cancer, history of bleeding tendencies with past or current use of antithrombotic drugs (aspirin or ticlopidine), anticoagulants (heparin, warfarin) and thrombolytic agents (streptokinase).

Those who are using investigational products or participated in any other clinical trials within 90 days prior to the initiation of trial were also excluded.
Admission and study protocol. The subjects were admitted at Clinical examination ward of UMMC a day in advance to study (Day 0). After signed informed consent was obtained from all subjects, physical examination and general health status including body temperature, heart rate and blood pressure were monitored by a medical physician. A standardised meal was provided and subjects were required to fast from 10 p.m onwards. On day 1, at 7 a.m, an in-dwelling cannula was placed in the antecubital vein of the subjects. A standardised breakfast which consists of 2 slices of white bread with chicken patty and warm water was provided following by the dosing. 5 mL of blood was drawn into EDTA tubes before and at 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, and 24 hours after dosing. Standardized meals consisting of lunch, tea break and dinner were served at 4, 8 and 11 hours after dosing. Subjects were allowed to be involved in non-strenuous activities after dosing; however, they had to be in upright position for ±2 hours.

During the study, a medical physician who was blinded to the study drugs was present to monitor the general condition of subjects including vital signs such as overall well-being, blood pressure and heart rate as well as possible adverse effects of the drugs. All events either mild or serious were recorded on adverse effect forms. After 24 hours, subjects were discharged following the last blood sampling. Additional blood samples were drawn at the last time-point for blood profile and clinical chemistry tests for safety monitoring. After a one week wash out period, subjects returned to the ward and to be given the other formulation (test or reference) and the same procedures were repeated.

Analysis of Plasma Samples. The plasma samples from this study were stored and analysed at Malaysian Palm Oil Board (MPOB). The HPLC method used to quantify concentrations of gamma and delta tocotrienol in plasma was validated as outlined in the USFDA Guidelines for Bioanalytical Analysis19. The parameters validated were specificity, linearity, accuracy, precision, recovery and stability.

The analysis of gamma and delta tocotrienols was performed using Agilent 1100 series HPLC System with ChemStation Software for LC System Rev. A.06.01, Instrument 2 Online (Agilent Technologies, Malaysia) equipped with a quaternary pump maintained at a pressure of 24 ± 1 bar, a fluorescent detector and a degasser. An autosampler was set at the injection volume of 100 μL for determination of samples. Chromatographic separations were achieved using Phenomenex Luna 5 μ silica 100 A ODS Hypersil column (250 × 4.60 mm i.d., 5 μm particle size; USA) operating at room temperature. The flow rate was set at 1 mL/min with excitation wavelength at 295nm and emission wavelength at 325nm. The total run time was 30 minutes. Isocratic elution was used and the mobile phase was prepared using 97.5% n-hexane, 2% Dioxane and 0.5% Isopropanol. The mobile phase was degassed by sonication prior to use. Liquid-liquid extraction method was used for plasma extraction. An internal standard, 2,2,5,7,8-Pentamethyl-6-hydroxychroman (PMC) was used.

Prior to use, liquid-liquid extraction method was used for plasma extraction. An internal standard, 2,2,5,7,8-Pentamethyl-6-hydroxychroman (PMC) was used.

The concentrations of quality controls of gamma and delta tocotrienols used were 3 μg/mL, 13 μg/mL and 23 μg/mL as low, medium and high quality controls respectively. The coefficient of variation (CV) of intraday and interday ranged from 1.06 to 3.47 for gamma tocotrienol while it was from 0.66 to 5.19 for delta tocotrienol. Meanwhile, accuracy percentage values for gamma and delta tocotrienols ranged from 95.32% to 108.30% and 95.81% to 110.14% respectively. Both gamma and delta tocotrienols were also found to be stable after three freeze-thaw cycles. Figures 1 and 2 show chromatograms of gamma and delta tocotrienols prepared in plasma and solvent respectively.

Pharmacokinetic analysis. Pharmacokinetic analysis was performed using non-compartmental analysis. All the pharmacokinetic parameters were calculated by using WinNonlin Professional version 5.3 (Pharsight Corporation, Mountain View, California). Peak plasma concentration (Cmax) and time to reach peak plasma concentration (Tmax) were obtained from the plasma concentration-time data. Area from time zero to last sampling time (AUC0–24) was determined using linear trapezoidal rule, while area from time zero to infinity (AUC0–∞) is the sum of AUC0–24 and AUCt–∞ (calculated by extrapolating plasma drug concentration (Ct) to the time axis and dividing it with elimination rate constant (ke)). Ke was obtained from the slope of linear regression of the ln-transformed plasma concentration-time curve in the elimination phase. The elimination half-life (t1/2) was determined using the following equation 1:

\[ t_{1/2} = \frac{\ln 2}{k_e} \] (1)

Statistical Analysis. The sample size for this study was estimated using a power calculation conducted on the basis of data obtained from earlier tocotrienol studies19. Analysis of Variance (ANOVA) was used to obtain the significance of the bioavailability values for Cmax and AUC0–∞. This was due to the variations that arise in cross-over studies in terms of subjects, formulations, sequences and periods. Analysis was conducted using WinNonlin Professional version 5.3. All the AUC and Cmax values were adjusted accordingly based on the dose given before ANOVA was performed.

Bioequivalence testing was based on the 90% CI for the ratio of the population means (test formulation/reference formulation) for Cmax and AUC21. The two formulations were considered to be bioequivalent only if the 90% CIs for the aforementioned values were within the predetermined bioequivalence
range of 80%–125%. The AUC and C\text{max} values were adjusted according to the dose given prior to ANOVA test. The difference in T\text{max} values between the two formulations was assessed using nonparametric Wilcoxon signed rank test using SAS Enterprise guide 5.1.

Results

Demographic characteristics. Twelve healthy subjects (9 males, 3 females) were enrolled in this study. Their mean age and BMI were 24 ± 1.65 (range, 22–27) and 23.43 ± 3.5 (range, 18.87–28.2). Eleven out of twelve subjects completed the trial (Table 1). One subject dropped-out from the trial due to difficulties in obtaining blood samples and considering her safety and well-being, she was withdrawn from the study. The venipuncture site was normal and the subject was fine when she was allowed to go home.

The mean plasma concentration for gamma and delta tocotrienol versus time in the test and reference formulations is presented in Figures 3 and 4. The pharmacokinetic parameters are shown in Tables 2 and 3 for gamma and delta tocotrienol, respectively. The mean values for C\text{max}, T\text{max}, AUC\text{0–24} and AUC\text{0–∞} for gamma-tocotrienol in GDT were 8406.75 ± 3670.99 μg/L, 5.64 ± 1.50 hours, 39811.07 ± 13336.74 μg/L*h and 41091.37 ± 13406.89 μg/L*h respectively; while for TRF, the values were 5604.67 ± 1971.73 μg/L, 4.73 ± 0.90 hours, 23312.73 ± 9804.14 μg/L*h and 24256.29 ± 10591.03 μg/L*h respectively.

Meanwhile, the mean values for C\text{max}, T\text{max}, AUC\text{0–24} and AUC\text{0–∞} for delta tocotrienol in GDT were 2693.89 ± 962.7 μg/L, 5.18 ± 0.40 hours, 12136.42 ± 6417.29 μg/L*h and 14627.95 ± 9792.93 μg/L*h respectively; while for TRF, the values were 2619.99 ± 1355.89 μg/L, 5.18 ± 1.83 hours, 10454.42 ± 6042.03 μg/L*h and 12453.83 ± 8875.65 μg/L*h respectively.

Tables 4 and 5 show the 90% CIs and the mean ratio of the test-to-reference formulations for C\text{max} and AUC\text{0–∞} for gamma and delta tocotrienols in the two different formulations. The bioequivalence analysis for CIs was based on the ratio of the population means (test formulation/reference formulation). These values were anti-logged and expressed as a percentage. The C\text{max} and AUC\text{0–∞} values for delta tocotrienol have been adjusted by dividing them with their respective dosage in the test and reference formulations.

For both gamma and delta tocotrienols, the 90% CI for both C\text{max} and AUC\text{0–∞} were beyond the bioequivalence limit of 80% to 125%. Hence, gamma and delta tocotrienols in both compounds were
Figure 2. Chromatogram of gamma delta tocotrienols and internal standard in solvent.

| Subject ID | Gender | Age | Height (cm) | Weight (kg) | BMI (kg/m²) |
|------------|--------|-----|-------------|-------------|-------------|
| 1          | M      | 22  | 178         | 84          | 26.51       |
| 2          | M      | 23  | 170         | 55          | 19.03       |
| 3          | M      | 24  | 166         | 52          | 18.87       |
| 4          | M      | 23  | 158         | 67          | 26.84       |
| 5          | M      | 22  | 157         | 69          | 27.93       |
| 6          | M      | 23  | 170         | 81.5        | 28.2        |
| 7          | F      | 23  | 155         | 55.5        | 23.1        |
| 8          | M      | 24  | 152         | 48          | 20.77       |
| 9          | F      | 26  | 157         | 51          | 20.69       |
| 10         | F      | 25  | 150         | 45          | 20.0        |
| 11         | M      | 26  | 173         | 76          | 25.39       |
| 12         | M      | 27  | 169         | 68          | 23.80       |

Mean ± SD 24 ± 1.65 162.92 ± 9.14 62.67 ± 13.36 23.43 ± 3.5

Minimum 22 150 45 18.87

Maximum 27 178 84 28.2

Table 1. Demographic data for healthy volunteers. BMI = Body mass index. M = Male. F = Female.
not bioequivalent. However, gamma tocotrienol in the test formulation was found to possess greater bioavailability in comparison to the gamma tocotrienol in the reference formulation. The significance in $T_{max}$ values were analysed using Wilcoxon signed rank test. The $T_{max}$ did not reach the significant statistical difference in both formulations for both gamma and delta tocotrienols.

Safety and Tolerability. This study is the first to test GDT with self-emulsification system in humans. No adverse events were observed or reported in the study. All laboratory blood test results for all the

Table 2. Mean pharmacokinetics parameters and bioequivalence results for Gamma Tocotrienol in 11 subjects after administration of GDT and TRF.

| PARAMETERS          | GDT3          | TRF           |
|---------------------|---------------|---------------|
| $T_{max}$ (h)       | 5.64 ± 1.50   | 4.73 ± 0.90   |
| $C_{max}$ (μg/L)    | 8406.75 ± 3670.99 | 5604.67 ± 1971.73 |
| $AUC_{0-24}$ (μg/L*h) | 39811.07 ± 13366.74 | 23312.73 ± 9804.14 |
| $AUC_{0-∞}$ (μg/L*h) | 41091.37 ± 13406.89 | 24256.29 ± 10591.03 |
| $K_{el}$ (1/h)      | 0.28 ± 0.12   | 0.31 ± 0.20   |
| Half-life (h)       | 2.97 ± 1.31   | 3.45 ± 2.50   |

Figure 3. Mean plasma (SD) concentration of Gamma Tocotrienol versus time after single oral dose of 600 mg GDT and 800 mg TRF.

Figure 4. Mean plasma (SD) concentration of Delta Tocotrienol versus time after single oral dose of 600 mg GDT and 800 mg TRF.
subjects were within clinically acceptable range for both periods indicating the safety and tolerability of the drug.

Discussion

In this study, we evaluated a newly developed GDT which only contained gamma and delta isomers of tocotrienol. This formulation was aimed to improve bioavailability of gamma and delta tocotrienols as these two isomers were reported to exert the most potent anti-cancer effects in several studies. These isomers increased the expression of Interleukin (IL)-24 mRNA which is associated with anti-tumour effects and decreased the levels of the pro-angiogenic cytokines, IL-6 and IL-8 in murine mammary cancer cells (4T1) and human umbilical vein endothelial cells (HUVEC)22,23. Apart from breast cancer, gamma tocotrienol has also been investigated in other types of cancer such as pancreatic24, hepatocellular25 and prostate cancer26 with favourable outcomes. Previous studies have reported that intake of tocotrienols with high fat meal increases its bioavailability as vitamin E is hydrophobic. Bile salts which will increase immensely after a high fat meal will emulsify the vitamin E and eventually form micelles that lead to increased bioavailability20,27. In this study, we have decided to administer the product after a normal standardized meal as both the formulations contained self-emulsifiers to aid in the absorption of tocotrienols across the intestinal wall. Furthermore, it was a real reflection when the patient takes the product regularly with food in their daily life. Biphasic absorption pattern was observed in the plasma profile of some volunteers for both test and reference formulations. The secondary peak may be attributed from the redistribution of drug due to the involvement of the entero-hepatic system20.

Table 3. Mean pharmacokinetics parameters and bioequivalence results for Delta Tocotrienol in 11 subjects after administration of GDT and TRF.

| Parameter          | GDT3                     | TRF                     | Ratio (%) | 90% CI (%) | Bioequivalence |
|--------------------|--------------------------|-------------------------|-----------|------------|----------------|
| Tmax (h)           | 5.18 ± 0.40              | 5.18 ± 1.83             |           |            |                |
| Cmax (μg/L)        | 2693.89 ± 962.77         | 2619.99 ± 1355.89       |           |            |                |
| AUC∞ (μg/L*h)      | 12136.42 ± 6417.29       | 10454.42 ± 6042.03      |           |            |                |
| AUC∞ (μg/L*h)      | 14627.95 ± 9792.93       | 12453.83 ± 8875.65      |           |            |                |
| Kel (1/h)          | 0.30 ± 0.28              | 0.38 ± 0.46             |           |            |                |
| Half-life (h)      | 5.48 ± 4.75              | 5.11 ± 4.94             |           |            |                |

Table 4. ANOVA results for mean maximum concentration (Cmax) and area under curve (AUC) from the time 0 hours to infinity for Gamma Tocotrienol. Analysis Of Variance (ANOVA).

| Parameter          | Treatment | Mean (n = 11) | Ratio (%) | 90% CI (%) | Bioequivalence |
|--------------------|-----------|---------------|-----------|------------|----------------|
| Cmax (μg/L)        | TRF       | 5604.67 ± 1971.73 | 144.08    | 106.21–195.46 | NO             |
|                   | GDT       | 8406.75 ± 3670.99  |           |            |                |
| AUC∞ (μg/L*h)      | TRF       | 24256.29 ± 10591.03 | 173.77    | 154.11–195.93 | NO             |
|                   | GDT       | 41091.37 ± 13406.89 |           |            |                |

Table 5. ANOVA results for mean maximum concentration (Cmax) and area under curve (AUC) (dose adjusted) from the time 0 hours to infinity for Delta tocotrienol.

| Parameter          | Treatment | Mean (n = 11) | Ratio (%) | 90% CI (%) | Bioequivalence |
|--------------------|-----------|---------------|-----------|------------|----------------|
| Cmax (μg/mL/mg)    | TRF       | 0.03 ± 0.01   | 72.23     | 52.35–99.66 | NO             |
|                   | GDT       | 0.02 ± 0.01   |           |            |                |
| AUC∞ (hr*μg/mL/mg) | TRF       | 0.10 ± 0.06   | 81.81     | 74.82–89.44 | NO             |
|                   | GDT       | 0.08 ± 0.04   |           |            |                |
was found in higher concentration in both benign and malignant tissue in contrast to delta tocotrienol. However, both gamma and delta tocotrienols concentrations were reduced in malignant breast lumps in comparison to the benign lumps. The morphology of the breast indicates that it is mainly composed of adipose tissue. Being a lipophillic compound with the presence of an unsaturated side chain, tocotrienols are able to penetrate efficiently into adipose tissue. The depletion of tocotrienols in malignant lumps might be associated with its antioxidiant property in quenching free radicals thereby suggesting its chemoprotective effect against breast cancer. Subsequently, Patel and colleagues (2012) looked at the levels of the isomers upon supplementation of TRF in surgical and normal patients. The concentration of gamma tocotrienol was found to be significantly higher in adipose tissue in comparison to delta tocotrienol. These findings further reinforces the notion that gamma tocotrienol plays a more prominent role in conferring protection against breast cancer.

Moreover, both formulations at the tested dose were found to be well tolerated in the healthy volunteers as no adverse events were observed and recorded during the entire period of the study. The findings from our study demonstrate that the 600 mg GDT and 800 mg TRF, the nearly equivalent dose of gamma and delta tocotrienols were not bioequivalent in the healthy volunteers. GDT has shown superior bioavailability in term of gamma tocotrienol as compared to TRF. Both test and reference formulations appeared to be generally safe and well-tolerated in all the subjects.

References
1. Nesaretnam, K., Guthrie, N., Chambers, A. F. & Carroll, K. K. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. *Lipids*. 30, 1139–43 (1995).
2. Nesaretnam, K. Multitargeted therapy of cancer by tocotrienols. *Cancer Lett.* 269, 388–395 (2008).
3. Kannappan, R., Gupta, S. C., Kim, J. H. & Aggarwal, B. B. Tocotrienols fight cancer by targeting multiple cell signalling pathways. *Genes Nutr.* 7, 43–52 (2012).
4. Vasanthi, H. R., Parameswari, R. P. & Das, D. K. Multifaceted role of tocotrienols in cardioprotection supports their structure: function relation. *Genes Nutr.* 7, 19–28 (2012).
5. Khanna, S. et al. Nanomolar vitamin E alpha-tocotrienol inhibits glutamate-induced activation of phospholipase A2 and causes neuroprotection. *J. Neurochem.* 112, 1249–1260 (2010).
6. Aggarwal, B. B., Sundaram, C., Prasad, S. & Kannappan, R. Tocotrienols the Vitamin E of the 21st century: its potential against cancer and other chronic diseases. *Biochem Pharmacol.* 80, 1613–1631 (2010).
7. Yuen, K. H., Wong, J. W., Lim, A. B., Ng, B. H. & Choy, W. P. Effect of mixed-tocotrienols in hypercholesterolemic subjects. *Funct Foods Health Dis.* 3, 106–117 (2011).
8. Toutain, P. L. & Bousquet-Mélou, A. Bioavailability and its assessment. *J. Vet. Pharmacol. Ther.* 27, 455–66 (2004).
9. Fairus, S., Nor, R. M., Cheng, H. M. & Sundram, K. Postprandial metabolic fate of tocotrienol-rich vitamin E differs significantly from that of alpha-tocopherol. *Am. J. Clin. Nutr.* 84, 835–42 (2006).
10. Fairus, S., Nor, R. M., Cheng, H. M. & Sundram, K. Alpha-tocotrienol is the most abundant tocotrienol isomer circulated in plasma and lipoproteins after postprandial tocotrienol-rich vitamin E supplementation. *J. Nutr.* 11, 5 (2012).
11. Yap, S. P., Yuen, K. H. & Lim, A. B. Influence of route of administration on the absorption and disposition of alpha-, gamma- and delta-tocotrienols in rats. *J. Pharm. Pharmacol.* 55, 53–58 (2003).
12. Yap, S. P. & Yuen, K. H. Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations. *Int J Pharm.* 281, 67–78 (2004).
13. Ramdas, P. et al. Tocotrienol-treated MCF-7 human breast cancer cells show down-regulation of AP1S and up-regulation of MIG6 genes. *Cancer Genomics Proteomics*. 8, 19–31 (2011).
14. Loganathan, R., Selvaduray, K. R., Nesaretnam, K. & Radhakrishnan, A. K. Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa B activity. *Cell Prolifer.* 46, 203–213 (2013).
15. Guthrie, N., Gapor, A., Chambers, A. F. & Carroll K. K. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. *J. Nutr.* 127, 544S–548S (1997).
16. International Conference on Harmonisation of Technical Requirements For Registration of Pharmaceuticals for Human Use. *ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1).* (1996) Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. (Accessed: 28th February 2014).
17. Ministry of Health Malaysia. *Malaysian Guideline for Good Clinical Practice.* (2011) Available at: http://www.rmc.upm.edu.my/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. (Accessed: 28th February 2014).
18. Ministry of Health. *Malaysian Guidelines for the conduct of bioavailability and bioequivalence studies.* (2000) Available at: http://apps.who.int/goodclinicalpractice/docs/s18594en/s18594en.pdf. (Accessed: 28th February 2014).
19. US Department of Health and Human Services (HHS), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). *Guidance for Industry: Bioanalytical Method Validation.* (2001) Available at: http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf. (Accessed: 22nd April 2014).
20. Yap, S. P., Yuen, K. H. & Wong, J. W. Pharmacokinetics and bioavailability of alpha- , gamma- and delta-tocotrienols under different food status. *J. Pharm Pharmacol.* 53, 67–71 (2001).
21. Schuurman, D. J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. *J Pharmacokin Biop.* 15, 657–680 (1987).
22. Selvaduray, K. R., Radhakrishnan, A. K., Kuty, M. K. & Nesaretnam K. Palm tocotrienols inhibit proliferation of murine mammary cancer cells and induce expression of interleukin-24 mRNA. *J. Interferon Cytokine Res.* 30, 909–916 (2010).
23. Selvaduray, K. R., Radhakrishnan, K. A. Kuty, M. K. & Nesaretnam, K. Palm tocotrienols decrease levels of pro-angiogenic markers in human umbilical vein endothelial cells (HUVEC) and murine mammary cancer cells. *Genes Nutr.* 7, 53–61 (2012).
24. Kunnunakkara, A. B. et al. Gamma-tocotrienol inhibits pancreatic tumor growth and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. *Cancer Res.* 70, 8695–705 (2010).
25. Rajendran, P. et al. Gamma-tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an anti-proliferative, pro-apoptotic and chemosensitizing agent. *Brit J Pharmacol.* 163, 283–298 (2011).
26. Yap, W. et al. Gamma tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. *Brit J Cancer.* 99, 1832–1841 (2008).
27. Fu, J. Y., Che, H. L., Tan, D. M. & Teng, K. T. Bioavailability of tocotrienols: evidence in human studies. *Nutr Metab.* 11, 5 (2014).
28. Nesaretnam, K., Gomez, P. A., Selvadurai, K. R. & Razak, G. A. Tocotrienol levels in adipose tissue of benign and malignant breast lumps in patients in Malaysia. *Asia Pac J Clin Nutr.* **16**, 498–504 (2007).

29. Patel, V. *et al.* Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. *J. Nutr.* **142**, 513–519 (2012).

**Acknowledgments**
This study was carried out with financial funding from PEMANDU/MPOB and HIR Grant UM.C/ HIR/MOHE/06 from the Ministry of Higher Education of Malaysia. We would like to thank Davos Life Science Pte. Ltd for the supply of Naturale Gamma Delta Tocotrienol capsules. We also extend our sincere appreciation to all officers and staffs of University Malaya Medical Centre (UMMC) and Malaysian Palm Oil Board (MPOB) for their contribution and support.

**Author Contributions**
Substantial contributions to conception and design: Z.C., N.A.T., H.G.F., N.B. & K.N. Acquisition of data: P.M., Z.C., R.B.C. & N.A.T. Analysis and interpretation of data: P.M., Z.C. & R.S.J. Drafting the article or reviewing it and, if appropriate, revising it critically for important intellectual content: Z.C., P.M., R.S.J. & N.A.T. Final approval of the version to be published: ALL authors (i.e. must make sure every author sees the last draft at least).

**Additional Information**
Competing financial interests: The authors declare no competing financial interests.

**How to cite this article**: Meganathan, P. *et al.* A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing Tocotrienol-Rich Fraction in healthy human subjects. *Sci. Rep.* **5**, 13550; doi: 10.1038/srep13550 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/